Product Reports Resources Pricing Login Book a demo

Curaleaf

Biotech & Life Sciences · Wakefield, United States · Founded 2010 · IPO 2018

Leading vertically integrated medical and wellness cannabis operator

Valuation $3.07B
Revenue $1.34B
EBITDA $246M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Talent graph

Curaleaf's talent

Book a demo to see the people
Employees mapped 2,844 incl. 4 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 9 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

1 investor on Curaleaf's cap table

Sourced from Dealroom's funding and investor records.

Series B+ 1 investor entered at this stage
Measure 8 Venture Partners

Global footprint

Where Curaleaf has talent and traffic

Workforce by country
7 countries with
team presence
🇺🇸 United States98.4%
🇬🇧 United Kingdom0.8%
🇵🇹 Portugal0.2%
🇨🇦 Canada0.1%
🇮🇳 India0.1%
Top 5 of 7 shown
Web traffic by country
1.9M monthly visits
across markets
🇺🇸 United States98.3%
🇨🇦 Canada0.5%
🇬🇧 United Kingdom0.5%
🇦🇺 Australia0.1%
🇩🇪 Germany0.1%
Top 5 markets shown

Patent intelligence

Curaleaf’s patent portfolio

Estimated portfolio value
$104k

5 active families in the valuation dataset.

Source: Dealroom Patent Intelligence · PatSnap. Portfolio estimates and the family records below have different coverage.

Compare patent portfolios across companies →

Capital deployed

Curaleaf's 12 investments and acquisitions.

Every disclosed deal where Curaleaf appeared as a backer or acquirer, 2019–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

12 deals across Curaleaf's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Curaleaf deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Curaleaf's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        12 of 12 deals

        Market sentiment

        What the market is saying about Curaleaf

        An AI-synthesized read of the highest-engagement posts about Curaleaf on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Curaleaf on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles